Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

The leaders of the Scottish Labour Party and the Scottish Green Party are among the signatories calling for this "game ...

Delawareans across the state are working toward a more inclusive and equitable health care system for residents. Here are ...

She is a certified HIV and HVC tester ... When Rep. Eric Morrison, a Glasgow Democrat, stepped into Legislative Hall, he was determined to make positive, statewide changes to Delaware’s ...

Experts urge South Africa to diversify its trade relationships and adapt to changing US policies following the cancellation ...

More than 30,000 people in the UK were infected with HIV and hepatitis C after they were given contaminated blood and blood products between the 1970s and early 1990s. Some 3,000 people died as a ...

Feb. 18, 2025 — Viruses, like those that cause COVID-19 or HIV, are formidable opponents once they invade our bodies. Antiviral treatments strive to block a virus or halt its replication.

The study, which was led by Professor Katie Robb from the University of Glasgow's School of Health and Wellbeing, involved 40,000 adults in the nationwide Scottish Bowel Screening Program.

Glasgow and the London Borough of Tower Hamlets—the study highlights the particular issues that minoritised ethnic communities face when essential services move largely online. Researchers found ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety trial, researchers report in The Lancet medical journal. Lenacapavir stops ...